The ranked leader in this dataset holds 548 of the 7,547 records in scope, with the field then dropping off steeply — the fifth-ranked assignee holds 165 and the tenth holds 147. Together the top 5 account for 18.0% of all records and the top 10 for 28.1%, meaning even the largest holders control only a minority share. The remaining records are spread across a long tail of 90 further ranked assignees plus unranked filers, so a single-company clearance check is not sufficient for freedom-to-operate work in this space.

No — filings peaked in 2018 at 407 records and have declined since, with the clearest complete-year comparison showing a fall from 340 filings in 2021 to 200 in 2024, a 41% drop. Figures for 2025 and 2026 appear lower still, but that reflects publication lag of roughly 18 months rather than an actual collapse in filing activity, since applications from those years are still clearing examination and publishing. The safest reading is that complete-year filing volume has cooled from its late-2010s high, not that the technology area is being abandoned.

Bioreactor and apparatus claims (IPC class C12M) appear in only 4.2% of the 7,547 records, and sterilising/disinfecting methods (A61L) in 3.4%, compared with 88.9% for core genetic-engineering claims under C12N. That gap suggests process engineering — closed-system bioreactor scale-up, automated passage protocols, and suspension-culture sterilisation — carries comparatively light claim density relative to the underlying cell biology. Teams building manufacturing hardware or process automation, rather than new reprogramming chemistry, are filing into thinner prior art.